Curaleaf Formally Launches Hostile Takeover Bid for Aurora Cannabis
CURLF sits 73% above its 52-week low of $5.4.
Summary
Curaleaf formally launched its hostile takeover bid for Aurora Cannabis, offering US$4.00 per share (45% premium) with a December 1, 2026 expiry. The bid is not subject to financing or due diligence conditions.
Key Events · M&A and Partnerships · CURLF
-
Formal Takeover Bid Launched
Curaleaf filed formal offer documents for its hostile takeover of Aurora Cannabis, offering US$4.00 per share (0.3463 Curaleaf shares plus US$0.75 cash), a 45% premium to Aurora's unaffected price.
-
Offer Expiry and Conditions
The offer expires December 1, 2026, and is subject to minimum tender of more than 50% of outstanding shares (66⅔% fully diluted), regulatory approvals, and no material adverse effect. No financing or due diligence conditions apply.
-
Cap Price Mechanism
The offer includes a cap price of US$5.00 per share; if Curaleaf's 20-day VWAP exceeds C$17.05, the exchange ratio adjusts to maintain the cap, limiting dilution to Curaleaf shareholders.
-
Strategic Rationale
The combined company would have over US$1.5 billion in LTM revenue and nearly US$350 million in LTM adjusted EBITDA, with at least US$40 million in annual cost synergies identified.
Analysis · CURLF · Life Sciences
Curaleaf has formally commenced its hostile takeover bid for Aurora Cannabis, filing the offer documents and setting a December 1, 2026 expiry. The offer values Aurora at US$4.00 per share, a 45% premium to its unaffected price, and includes a cap price mechanism to limit dilution. The bid is not subject to financing or due diligence conditions, increasing the likelihood of completion. This is a major strategic move that could create the world's largest cannabis company with over US$1.5 billion in revenue, but it also carries significant integration and regulatory risks.
At the time of this filing, CURLF was trading at $9.34 on OTC in the Life Sciences sector, with a market capitalization of approximately $2.5B. The 52-week trading range was $5.40 to $15.15. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.